The TB world calls for redoubling of efforts for a TB vaccine, after disappointing results from first TB vaccine efficacy study in a century.
Results of a first-of-its-kind clinical trial of a novel TB vaccine has demonstrated that the candidate was safe and well tolerated, but that it did not confer efficacy in prevention of TB disease when administered as a boost to Bacille Calmette-Guerin (BCG), the currently used TB vaccine. The clinical trial of the TB vaccine candidate MVA85A took place among 2,797 infants living in the Western Cape province of South Africa.
The ultimate game-changer in the battle to eliminate TB would be a new vaccine that prevents children and adults from developing and transmitting the disease, which leads to 1.4 million deaths each year.
Find out more on the AERAS website.
Comments are closed.